Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029
Summary Ulcerative colitis (UC) is a type of inflammatory bowel disease.In UC, chronic inflammation affects the colon (also known as the large intestines).
Initially, UC usually manifests in the terminal part of the colon, the rectum, and is termed ulcerative proctitis.It can extend to the entire left part of the colon (left-sided proctitis) or the entire colon (pancolitis).
The current UC market is overcrowded with cheap generic drugs for mild to moderate disease, expensive biologics such as anti-tumor necrosis factors (TNFs) and anti-integrins, and biosimilars for severe disease that are used as short- or long-term alternatives to surgical options.The R&D within this space consists of 10 late-stage pipeline drugs with five oral formulations, more convenient dosing frequencies, novel mechanisms of action (MOAs), and improved safety profiles and drug availability.
However, the pipeline products will be challenged by the increasing emergence of biosimilars, since the major brands will experience patent cliffs throughout the forecast period. Furthermore, all but one drug are being developed for moderate to severe UC, which will result in a crowded market.
This model covers the market forecast for the marketed and late-stage pipeline UC therapeutics.The model segments patients by severity, with mild-moderate, moderate-severe, and severe/fulminant segments.
The base year of this model is 2019, and the forecast period is 2020-2029.
KEY QUESTIONS ANSWERED
- Which unmet needs are limiting the treatment of ulcerative colitis in the 8MM? - What strategies can the pharmaceutical industry employ to increase treatment rates for ulcerative colitis? How should these strategies differ across different geographical markets? - What effect will the launch of biosimilars and generics have on the sales of branded agents? - What are the main R&D trends in the ulcerative colitis market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
Key Highlights - The greatest drivers of growth in the global UC market include the launch of 10 new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 8MM countries. - The main barriers to growth in the UC market include the crowded and competitive market as well as patent expiration of key biologic brands with subsequent biosimilar launch. - Novel drug classes in the UC pipeline include IL-23 inhibitors and S1P receptor modulators. In addition, Takeda will launch a subcutaneous version of their product, Entyvio, and two additional JAK inhibitors are expected to make their appearance on the market. - The most important unmet needs in the UC market are for safer and more effective therapies, an improvement in management of fulminant patients, biomarkers to predict responsiveness to therapy, and standardization of patient-reported outcomes.
Scope - Overview of UC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Topline UC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period. - Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 8MM. - Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy The report will enable you to - - Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines. - Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global UC therapeutics market from 2019-2029. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Our reports have been used by over 10K customers, including:
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 Summary Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out...
The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The growth of this market is driven owing to the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing...
Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs
The global spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), throughout 2020 has led to widespread disruption of daily life, leading to national lockdowns in attempts to mitigate...
181 pages •
By The Business Research Company
• Dec 2020
Human Microbiome Therapeutics Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global human microbiome therapeutics market. Description: Where is the largest and fastest growing...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
257 pages •
By The Business Research Company
• Dec 2020
Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications And Growth provides the strategists, marketers and senior management with the critical information they need to assess the global anti-viral drug therapy market. Description: Where is the largest and fastest growing...
Insomnia - Pipeline Review, H2 2020
latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2020, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.
Insomnia is a sleep disorder that is characterized by difficulty...
Diagnostic Imaging Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.